Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
March 1, 1987
An integrated system for interstitial 192Ir implants
J D Bourland, K L Reynolds, E L Chaney, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 4, 2008
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer
Thomas E Stinchcombe, Carrie B Lee, Dominic T Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2004
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer
Daniel B Fried, David E Morris, Charles Poole, et al.
International Journal of Surgical Oncology
|
February 8, 2012
Concomitant radiotherapy and chemotherapy for high-risk nonmelanoma skin carcinomas of the head and neck
Smith Apisarnthanarax, Nirav Dhruva, Farhad Ardeshirpour, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 4, 2012
Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study
Jordan A Holmes, Andrew Z Wang, Karen E Hoffman, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 28, 2006
Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy
Thomas E Stinchcombe, David E Morris, Dominic T Moore, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 20, 2008
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer
Carrie B Lee, Thomas E Stinchcombe, Dominic T Moore, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 4, 2012
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma
Daniel S Higginson, Ronald C Chen, Gregg Tracton, et al.
Cancer
|
August 10, 2000
Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial
M A Socinski, J G Rosenman, M J Schell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 5, 2008
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer
Thomas E Stinchcombe, David E Morris, Carrie B Lee, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
International Journal of Radiation Oncology, Biology, Physics
|
March 1, 1987
An integrated system for interstitial 192Ir implants
J D Bourland, K L Reynolds, E L Chaney, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 4, 2008
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer
Thomas E Stinchcombe, Carrie B Lee, Dominic T Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2004
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer
Daniel B Fried, David E Morris, Charles Poole, et al.
International Journal of Surgical Oncology
|
February 8, 2012
Concomitant radiotherapy and chemotherapy for high-risk nonmelanoma skin carcinomas of the head and neck
Smith Apisarnthanarax, Nirav Dhruva, Farhad Ardeshirpour, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 4, 2012
Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study
Jordan A Holmes, Andrew Z Wang, Karen E Hoffman, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 28, 2006
Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy
Thomas E Stinchcombe, David E Morris, Dominic T Moore, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 20, 2008
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer
Carrie B Lee, Thomas E Stinchcombe, Dominic T Moore, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 4, 2012
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma
Daniel S Higginson, Ronald C Chen, Gregg Tracton, et al.
Cancer
|
August 10, 2000
Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial
M A Socinski, J G Rosenman, M J Schell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 5, 2008
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer
Thomas E Stinchcombe, David E Morris, Carrie B Lee, et al.
Page
of 6